Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
177
resultados
Última actualización
04/05/2025 [07:05:00]
Resultados 75 a 100 de 177
Resumen de: AU2023361023A1
The invention relates to pharmaceutical product comprising a polynucleotide for use in the prevention or treatment of a SARS-CoV-2 virus infection wherein said SARS-CoV-2 virus is not a Wuhan wild-type SARS-CoV-2 virus. The polynucleotide encodes an attenuated human coronavirus or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons, wherein a one-to-stop codon is i) a different but synonymous codon compared to the corresponding codon in a natural human coronavirus genome and ii) differs by one nucleotide from a STOP codon.
Resumen de: US2025109186A1
Certain embodiments of the invention provide isolated anti-SARS-CoV-2 sdAbs, as well as polypeptides and protein molecules comprising such sdAbs. Certain embodiments of the invention also provide methods of using these sdAbs, polypeptides and protein molecules for treating or preventing a SARS-CoV-2 infection.
Resumen de: US2025109187A1
The present invention provides antibodies that bind to the SARS-CoV-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.
Resumen de: US2025109173A1
Provided is a recombinant polypeptide containing at least one immunogenic fragment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) spike glycoprotein, and pharmaceutical compositions containing the same.
Resumen de: US2025108107A1
Provided herein are SARS-CoV-2 spike proteins and polypeptides (e.g., SARS-CoV-2 spike proteins and polypeptide immunogens (and immunogenic fragments and immunogenic variants thereof)) comprising at least one set of amino acid substitutions, and nucleic acid molecules encoding the same. Further provided herein are compositions (e.g., pharmaceutical compositions) and vaccines comprising the same for use in e.g., the prevention, treatment, and/or amelioration of a SARS-CoV-2 infection.
Resumen de: WO2025067013A1
An anti-SARS-CoV-2 virus protein or mRNA vaccine, a preparation method therefor, and a use thereof. The protein has one or more amino acid residues added, deleted, or replaced in the amino acid sequence as shown in SEQ ID NO: 18. The nucleic acid encodes an S protein mutant. Preclinical animal test data shows that the mRNA vaccine has a good protective effect for the current variants of concern (VOC) of the SARS-CoV-2 virus and has broad clinical application prospects.
Resumen de: US2025108106A1
This disclosure is directed to a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a polymer-drug nanoaggregate having a polymer and at least one bioactive agent that can comprise STING polypeptide, a nucleic acid encoding said STING polypeptide, a STING inhibitor, a STING activator, a STING agonist, a STING antagonist, a STING modulating molecule, or a combination thereof. The pharmaceutical composition can be a vaccine or an adjuvant for a vaccine. This disclosure is also directed to a method for treating or preventing a disease using the pharmaceutical composition. The disease can include infectious diseases caused by viruses or other pathogens, for example, influenza, rabies, or respiratory illnesses such as severe acute respiratory syndrome (SARS) caused by coronaviruses, such as MERS-CoV, SARS-CoV, and Coronavirus Disease 2019 (COVID-19) caused by the virus SARS-CoV-2 and its variants.
Resumen de: US2025108108A1
A hybrid vaccine composition that prevents infection or reinfection by both influenza and coronaviruses, comprising at least a portion of a Coronavirus spike(S) protein and at least a portion of at least one influenza hemagglutinin (HA) protein. The portion of the coronavirus spike(S) protein is highly conserved among human and animal coronaviruses. The vaccine composition may comprise a Coronavirus protein comprising either: a structural protein, e.g., a Spike protein, a Nucleocapsid protein, or a combination thereof, or a non-structural protein, e.g., NSP2, NSP3, NSP14, or combination thereof; and at least a portion of at least one influenza hemagglutinin (HA) protein.
Resumen de: US2025110112A1
Methods for diagnosing a subject for a COVID-19 infection state include collecting an alveolar air breath sample from a subject; passing the breath sample into contact with a volatile organic compound (VOC) sensor operable to detect a plurality of VOC biomarkers for a COVID-19 infection state; producing a readable sensor output for at least two of the plurality of biomarkers; and diagnosing the COVID-19 infection state of the subject based on the readable sensor output. Systems for detecting and identifying at least one VOC biomarker for a COVID-19 infection state in exhaled breath of a subject include a mouth piece connected to a housing, the mouth piece operable to receive the exhaled breath of the subject; a sensor module disposed in the housing, the sensor module operable to detect the at least one VOC biomarker in the exhaled breath, and further operable to produce a readable sensor output for the at least one VOC biomarker; and a communication module disposed in the housing and in communication with the sensor module, the communication module operable to transmit collected data from the sensor module.
Resumen de: WO2025067202A1
Provided herein are methods for treating or preventing a disease caused by veterinary coronavirus in a non-human animal suffering from coronavirus infection, in particular, feline coronavirus infection.
Resumen de: AU2023341167A1
The present disclosure relates to methods of treating Alzheimer's disease, diseases and/or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance comprising administration of a therapeutically-effective combination of a COX-2 inhibitor and an antiviral compound.
Resumen de: AU2023347083A1
This disclosure relates to RNA interference (RNAi) reagents for treatment of SARS-CoV-2 infection, compositions comprising same, and use thereof to treat or prevent infection by SARS- CoV-2.
Resumen de: AU2023334598A1
A method and an apparatus utilizing targeted ion mobility spectrometry for the detection of the SARS-CoV-2 virus and its variants, by measuring the quantity of free polyamines including putrescine, spermidine, and spermine in a sublingual saliva sample. Other embodiments are capable of providing instant, cost effective, POC testing and test results for other viral and bacterial infections including influenza, acute and chronic respiratory conditions, certain forms of inflammation, and the detection of certain abnormal cells in human subjects.
Resumen de: WO2025072888A2
The present invention provides antibodies that bind to the SARS-CoV-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.
Resumen de: AU2023329395A1
The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein and/or engineered nucleocapsid protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display and nucleocapsid-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple SARS-CoV-2 variants.
Resumen de: AU2023336178A1
The invention relates to a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein 7, non-structural protein 8, non-structural protein 9, non-structural protein 10, non-structural protein 11, non-structural protein 12, an endoribonuclease, and a 2'-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome, and wherein the polynucleotide further comprises a furin cleavage site modification resulting in a loss of a furin cleavage site being naturally present in the SARS-CoV-2 genome. The invention further relates to a live attenuated SARS- CoV-2 comprising this polynucleotide, to a vaccine comprising this live attenuated SARS-CoV-2, as well as to associated methods.
Resumen de: US12266425B1
Provided are methods of assessing a biological sample obtained from an individual for the presence of a T cell that expresses a T cell receptor (TCR) comprising a TCRβ CDR3 sequence set forth in Table 1. Such methods further comprise identifying the individual as having COVID-19 when the presence of the TCR is detected. The presence of one or more of these TCRs may be of use in prognosticating severity of COVID-19 in the individual and the individual may be treated based on the expected severity of COVID-19. Treatment methods may include administering to the individual a T cell engineered to express the TCR. Such engineered T cells are also disclosed. Also provided are compositions and multimers that find use, e.g., in practicing the methods of the present disclosure.
Resumen de: KR20230153844A
The present invention relates to a biomarker for predicting or diagnosing COVID-19 severity, use thereof, a method for screening candidate substances for preventing, treating, or alleviating COVID-19, a biomarker for predicting or monitoring the progress of COVID-19, and use thereof. According to the present invention, the biomarker can accurately determine whether COVID-19 severity is present and can clearly determine the condition of a lesion and whether a patient improves after treatment. A biomarker composition for predicting or diagnosing COVID-19 severity comprises at least one selected from a group consisting of NEAT1, MALAT1, and combinations thereof, or a gene encoding the same.
Resumen de: US2024376178A1
The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Resumen de: US2025101085A1
In order to provide a novel human-derived monoclonal antibody that binds to a spike (S) protein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to neutralize SARS-CoV-2, an antigen-binding fragment thereof, and a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof, the present invention provides: a human-derived monoclonal antibody against SARS-CoV-2, the antibody binding to the S protein of SARS-CoV-2 to neutralize viral activity of the S protein including an immune escape mutation; an antigen-binding fragment thereof; nucleic acids encoding the antibody and the antigen-binding fragment thereof; and a pharmaceutical composition for treating or preventing a SARS-CoV-2 coronavirus infectious disease, the pharmaceutical composition containing the antibody or the antigen-binding fragment thereof.
Resumen de: US2025101427A1
In alternative embodiments, provided are methods for eradicating or reducing the in vivo numbers of cancer stem cells comprising administering to an individual in need thereof an ADAR1 (adenosine deaminase associated with RNA1) inhibiting agent, wherein the ADAR1 inhibiting agent reduces, or significantly reduces, ADAR1 Nano-luc reporter activity in cell lines and in human cancer stem cell assays. In alternative embodiments, provided are methods for inhibiting an RNA virus or a retrovirus, optionally a SARs-COV-2 virus, comprising lentiviral ADAR1 overexpression and in vivo administration, optionally intravenous (IV) administration, of a lentiviral ADAR1 transduced stem cell, optionally the stem cell is a cord blood CD34+ cell or a mesenchymal stromal cell.
Resumen de: US2025099444A1
Methods of treating a subject for long-haul COVID are provided. Aspects of the methods include administering to the subject a tropane CCR5/CCL5 interaction inhibitor in combination with a statin to treat the subject for long-haul COVID. Also provided are compositions for use in practicing the methods.
Resumen de: US2025099474A1
The present invention provides a pharmaceutical composition containing a coronavirus 3CL protease inhibitor for treating novel coronavirus infections (COVID-19).A pharmaceutical composition for treating novel coronavirus infections (COVID-19) is provided, the composition containing, as an active ingredient, a complex that contains:a compound represented by Formula (I):andfumaric acid.
Resumen de: US2025099424A1
The invention relates to compounds of Formula I″wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
Nº publicación: WO2025062057A1 27/03/2025
Solicitante:
UNIV DE MALAGA [ES]
UNIV MIGUEL HERNANDEZ DE ELCHE [ES]
UNIVERSIDAD DE M\u00C1LAGA,
UNIVERSIDAD MIGUEL HERN\u00C1NDEZ DE ELCHE
Resumen de: WO2025062057A1
The present invention relates to 5-fluorouracil (5-FU) for use thereof as an antiviral, alone or in combination with peptides that inhibit binding between nsp10 and nsp14 and between nsp10 and nsp16, acting against viruses of the family Coronaviridae, preferably SARS-CoV-2.
BOPI
Sede Electrónica
